Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.074 AUD | -2.63% | -5.13% | +7.25% |
Apr. 17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
Apr. 17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+7.25% | 49.92M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- NTI Stock
- News Neurotech International Limited
- Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism